Renaissance Technologies LLC’s Bridgebio Pharma Inc (BBIO) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Renaissance Technologies LLC first reported Bridgebio Pharma Inc in Q2 2025. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased across later filings. Renaissance Technologies LLC currently reports 856.85K shares. The latest verified filing showed: Bought 134.3% more.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $74.48
Filing context
Quarter-end price $74.26
Filing context
Quarter-end price $43.18
How important is Bridgebio Pharma Inc in Renaissance Technologies LLC’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Market context only; not an investor transaction price.
Derived from validated reported value and shares where supported.
Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Renaissance’s secret models, complete trading book, exact trade dates or execution prices.